Loading...
Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: emphasis on ponatinib
The advent of tyrosine kinase inhibitors (TKIs) targeted therapy revolutionized the treatment of chronic myeloid leukemia (CML) patients. However, cardiotoxicity associated with these targeted therapies puts the cancer survivors at higher risk. Ponatinib is a third-generation TKI for the treatment o...
Saved in:
| Published in: | Int J Cardiol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8095092/ https://ncbi.nlm.nih.gov/pubmed/32470534 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijcard.2020.05.077 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|